SB-408124

SB-408124
Identifiers
	IUPAC name 1-(6,8-difluoro-2-methylquinolin-4-yl)-3-[4-(dimethylamino)phenyl]urea;
CAS Number	288150-92-5 ;
PubChem CID	4331799;
IUPHAR/BPS	1704;
ChemSpider	3536200 ;
CompTox Dashboard (EPA)	DTXSID20402022 ;
ECHA InfoCard	100.164.461
Chemical and physical data
Formula	C19H18F2N4O
Molar mass	356.377 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c3cc(N(C)C)ccc3NC(=O)Nc1cc(C)nc2c1cc(F)cc2F;
	InChI InChI=1S/C19H18F2N4O/c1-11-8-17(15-9-12(20)10-16(21)18(15)22-11)24-19(26)23-13-4-6-14(7-5-13)25(2)3/h4-10H,1-3H3,(H2,22,23,24,26) ; Key:JTARFZSNUAGHRB-UHFFFAOYSA-N ;
(what is this?) (verify)

SB-408124 is a drug which is a non-peptide antagonist selective for the orexin receptor subtype OX₁, with around 70x selectivity for OX₁ over OX₂ receptors, and improved oral bioavailability compared to the older OX₁ antagonist SB-334867. It is used in scientific research into the function of orexinergic neurons in the body.[1][2]

References

Langmead CJ, Jerman JC, Brough SJ, Scott C, Porter RA, Herdon HJ (January 2004). "Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor". British Journal of Pharmacology. 141 (2): 340–6. doi:10.1038/sj.bjp.0705610. PMC 1574197. PMID 14691055.
Peng HY, Chang HM, Chang SY, Tung KC, Lee SD, Chou D, et al. (July 2008). "Orexin-A modulates glutamatergic NMDA-dependent spinal reflex potentiation via inhibition of NR2B subunit". American Journal of Physiology. Endocrinology and Metabolism. 295 (1): E117-29. doi:10.1152/ajpendo.90243.2008. PMID 18477704.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Langmead CJ, Jerman JC, Brough SJ, Scott C, Porter RA, Herdon HJ (January 2004). "Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor". British Journal of Pharmacology. 141 (2): 340–6. doi:10.1038/sj.bjp.0705610. PMC 1574197. PMID 14691055.

[2] Peng HY, Chang HM, Chang SY, Tung KC, Lee SD, Chou D, et al. (July 2008). "Orexin-A modulates glutamatergic NMDA-dependent spinal reflex potentiation via inhibition of NR2B subunit". American Journal of Physiology. Endocrinology and Metabolism. 295 (1): E117-29. doi:10.1152/ajpendo.90243.2008. PMID 18477704.